ABSTRACT
OBJECTIVE: Routine outcome monitoring (ROM) has been strongly endorsed by psychotherapy researchers, but has yet to achieve widespread implementation in clinical settings. This article describes the development of the Clinically Adaptive Multidimensional Outcome Survey (CAMOS), an innovative ROM system that allows for local adaptation while providing high quality data. METHOD: Three-hundred and four clients at a university counseling center and 211 female patients at an eating disorder treatment facility were administered the CAMOS at intake, and 118 took the CAMOS at both intake and discharge. Two models were developed and compared. Both models were developed using exploratory and confirmatory factor analysis. RESULTS: A five-factor model was found to have the best model fit, internal consistency, convergent validity, and discriminant validity. CONCLUSIONS: The CAMOS has evidence to support its reliability and validity as a measure of various dimensions of distress. Distinctive tailoring features of the CAMOS compared to other ROM measures are described.
Subject(s)
Mental Disorders/therapy , Models, Statistical , Outcome Assessment, Health Care/methods , Psychometrics/methods , Psychotherapy , Adult , Evidence-Based Practice , Factor Analysis, Statistical , Feeding and Eating Disorders/therapy , Female , Humans , Male , Middle Aged , Outcome Assessment, Health Care/standards , Psychometrics/instrumentation , Psychometrics/standards , Psychotherapy/statistics & numerical data , Reproducibility of Results , Young AdultABSTRACT
OBJECTIVE: Neonates who are treated with low-molecular-weight heparin require repeated venipunctures to monitor anti-factor Xa (anti-FXa) levels. Generally, blood withdrawn from umbilical artery catheters (UACs) is not useful for such monitoring because heparin in the fluids running through the catheters contaminates the results. We tested methods for collecting blood for anti-FXa levels from UACs through which heparin-containing fluids were running, in an attempt to reduce the need for repeated venipunctures of anticoagulated neonates. STUDY DESIGN AND METHODS: A new blood drawing port, through which no heparin was run, was added to the UAC system. Qualifying neonates with UACs were randomized to have anti-FXa levels drawn after line-clearing volumes of 0.5, 3.0, or 4.0 ml. RESULTS: Twelve patients with UACs were enrolled and all completed the study with no adverse events. When 0.5, 3.0, or 4.0 ml of blood was cleared from the UAC before withdrawing the test sample, heparin contaminated the test (anti-FXa levels > or = 0.1 U/ml) in 66%, 16%, and 8% of samples, respectively. Differences between the 0.5- vs. 3.0-ml line-clearing volumes and between the 0.5- vs. 4.0-ml clearing volumes were significant (p = 0.0026 and 0.0006, respectively). CONCLUSION: Blood samples for anti-FXa can be drawn from UACs through which heparin-containing solutions are infusing if a port is added through which no heparin-containing fluids are run, a line-clearing volume of at least 4.0 ml is drawn, and a contamination rate of 8% of samples is acceptable.
Subject(s)
Catheterization, Central Venous/instrumentation , Factor Xa/analysis , Thrombosis/blood , Umbilical Arteries , Catheterization, Central Venous/methods , Equipment Design , Equipment Safety , Female , Heparin/therapeutic use , Humans , Infant, Newborn , Intensive Care Units, Neonatal , Male , Monitoring, Physiologic/methods , Probability , Sensitivity and Specificity , Thrombolytic Therapy/methods , Thrombosis/drug therapy , Thrombosis/prevention & controlABSTRACT
BACKGROUND: The etiology of Henoch-Schönlein purpura (HSP) has been ascribed to a variety of infectious and noninfectious agents. Because we encountered a patient with HSP who had evidence of Bartonella henselae infection and a prior report of a patient with systemic cat-scratch disease presenting as leukoclastic vasculitis, we investigated the association of B. henselae infection with HSP. METHODS: We determined the antibody titers to B. henselae on the sera of 18 patients with HSP and on 57 controls. All patients presented with the characteristic leukoclastic rash of HSP. About one-half of the patients had joint or abdominal symptoms, and four had hematuria at presentation. An indirect immunofluorescent assay was used to determine serum antibody titers to B. henselae. Sera that were reactive at a dilution of 1/64 were considered positive. RESULTS: Eight of the 57 (14%) control sera and 12 of the 18 (67%) patient sera were positive for B. henselae antibody (P < 0.0001). CONCLUSION: The results of this study indicate a significant association of antecedent B. henselae infection with HSP. The frequency of this association (67%) exceeds that of previously ascribed etiologic agents for this disease, such as the group A Streptococcus.
